Autoimmunity and Autoinflammation: From Genes and Cells to Tissues and Therapies (S8)
February 13-16, 2028
| Fairmont Monte Carlo, Monte Carlo, Monaco
Christopher D. Buckley, Ellen M. Gravallese and Luke Devey
Sunday, February 13, 2028
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Monday, February 14, 2028
| 8:00–8:30 AM |
Poster Setup |
|
| 8:15–5:00 PM |
Poster Viewing |
|
| 8:30–8:40 AM |
Welcome Remarks |
|
| 8:40–9:30 AM |
Keynote Address |
|
| |
Carl H June †, University of Pennsylvania
From Autologous CAR-T to Programmable Immune Reset: The Next Era of Cell Therapy in Autoimmunity |
|
| 9:30–11:45 AM |
From Genetic Architecture to Causal Cell States and Therapeutic Hypotheses |
|
| |
Sophie Hambleton †, Newcastle University
Inborn Errors of Immunity as Windows into Autoimmunity and Autoinflammation |
|
| |
Daphne Koller †, insitro
From Human Data to Medicines: Machine Learning for Target Discovery and Patient Stratification |
|
| |
James C. Lee †, Francis Crick Institute
From Genetic Risk to Pathogenic Macrophage Programs: ETS2 and Therapeutic Targets in IBD |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 10:00–10:20 AM |
Coffee Break |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Data-Driven Approaches to Tissue Immunity in Autoimmune and Inflammatory Disease |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Innate and Barrier Immune Circuits that Initiate and Sustain Disease |
|
| |
Charlotte Odendall †, King's College London
Interferon and Innate Signaling at Mucosal Barriers: When Host Defense Becomes Tissue Inflammation |
|
| |
Megan T. Baldridge †, Washington University School of Medicine
Microbiota–Innate Immune Circuits in Barrier Inflammation |
|
| |
Eva Frickel †, University of Geneva
Cell-Intrinsic Immunity and Intracellular Stress: New Entry Points into Chronic Inflammation |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Tuesday, February 15, 2028
| 8:00–8:30 AM |
Poster Setup |
|
| 8:15–5:00 PM |
Poster Viewing |
|
| 8:30–11:30 AM |
From Mechanism to Patient Stratification and Disease Interception |
|
| |
Ellen M. Gravallese, Brigham and Women's Hospital
Tissue Damage, Repair, and Therapeutic Response in Inflammatory Arthritis |
|
| |
Saurabh Mehandru †, Icahn School of Medicine
Human Tissue Immunity in IBD: Linking Mucosal Cell States to Treatment Response |
|
| |
Pablo Pelegrin †, University of Murcia
From Inflammasome Biology to Biomarkers, Patient Stratification, and Targeted Therapy |
|
| |
Uptal Patel †, Biogen
Precision Therapeutics for Autoantibody-Mediated Kidney Disease: Translating Plasma-Cell Biology into Clinical Development |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Resetting Tissue Homeostasis - Regulatory Pathways, Stromal Circuits, and Fibrosis |
|
| |
Christopher D. Buckley, Kennedy Institute of Rheumatology
The Cellular Basis of persistent Inflammation and its Location: From Tissue Niches to Therapeutic Targets |
|
| |
Jo L Viney †, Seismic Therapeutic
Immune Agonism and Regulatory Pathways as Therapeutic Strategies in Autoimmunity |
|
| |
Adam P Croft †, University of Birmingham
Resetting the Tissue: Targeting Fibroblasts to Provide New Medicines for Fibrotic and Autoimmune Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Wednesday, February 16, 2028
| 8:30–11:30 AM |
Immune Reset in the Clinic - CAR-T, T-Cell Engagers, and Engineered Tolerance |
|
| |
Georg A Schett †, Uniklinikum Erlangen
Deep B-Cell Depletion and Immune Reset with CAR-T in Lupus and Systemic Sclerosis |
|
| |
Jeff Jones †, Cullinan Therapeutics
Off-the-Shelf Immune Reset with CD19- and BCMA-Directed T-Cell Engagers in Autoimmune Disease |
|
| |
Luke Devey, Quell Therapeutics
Engineered Regulatory T Cells: Can Tolerance Replace Depletion? |
|
| |
Aimee S. Payne †, Columbia University
Antigen-Specific Cellular Therapy for Autoantibody-Mediated Disease: From CAAR-T to Next-Generation Immune Engineering |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Next-Generation Immune Engineering and Therapeutic Platforms |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Beyond First-Generation CAR-T - In Vivo, Allogeneic, and Myeloid Cell Engineering |
|
| |
Laura K. Shawver †, Birdseye Therapeutics
In Vivo CAR-T for Autoimmunity: Turning Cell Therapy into a Scalable, Off-the-Shelf Medicine |
|
| |
Blake Aftab †, Adicet Bio, Inc.
Allogeneic Gamma-Delta CAR-T for Lupus and Systemic Sclerosis: Toward an Off-the-Shelf Immune Reset |
|
| |
Saar I. Gill †, University of Pennsylvania
Engineering Myeloid Cells to Reprogram Fibrotic and Inflamed Tissues |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Thursday, February 17, 2028
